QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
August 25, 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment...